The National Heart, Lung, and Blood Institute (NHLBI) is currently seeking public feedback that will inform future research the agency will conduct on inhibitors to factor VIII (FVIII) in patients with hemophilia A. To this end, the NHLBI has released a Request for Information (RFI) to solicit perspectives and comments from the bleeding disorders community on potential strategies, scientific opportunities and priorities, and the requisite infrastructure to optimize inhibitor research.
The goal is to advance the fundamental scientific understanding of the human immune response to FVIII that will allow healthcare providers to both identify hemophilia A patients most at risk for an inhibitor and to mitigate those modifiable risk factors to forestall an undesired immune response. Investigators will also look to uncover optimal treatment strategies to tackle inhibitors at their onset.
All RFI responses must be submitted via email to FactorVIII@nhlbi.nih.gov by November 12, 2018. Please include the notice number NOT-HL-18-652 in the subject line. Access this link to view the full list of topics on which the NHLBI is seeking comments and to learn more about how to submit an email response.
